CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analyst Ratings as of May 16, 2018

May 16, 2018 - By Kristin Houston

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Ratings Coverage

In total 8 analysts cover CymaBay Therapeutics (NASDAQ:CBAY). “Buy” rating has 8, “Sell” are 0, while 0 are “Hold”. (NASDAQ:CBAY) has 100% bullish analysts. 16 are the (NASDAQ:CBAY)’s ratings reports on May 16, 2018 according to StockzIntelligence Inc. On Thursday, January 25 the stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) has “Buy” rating given by Roth Capital. On Wednesday, January 31 the stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by Piper Jaffray. The company rating was maintained by Roth Capital on Monday, April 16. On Tuesday, November 28 the firm has “Buy” rating given by Leerink Swann. The stock rating was maintained by Oppenheimer with “Buy” on Wednesday, March 21. On Wednesday, January 10 the firm earned “Buy” rating by Oppenheimer. On Wednesday, March 28 the firm earned “Buy” rating by Leerink Swann. In Wednesday, May 9 report Oppenheimer maintained the stock with “Buy” rating. On Wednesday, April 11 the firm has “Buy” rating by Leerink Swann given. On Friday, March 16 the stock has “Buy” rating by Cantor Fitzgerald. Listed here are CymaBay Therapeutics, Inc. (NASDAQ:CBAY) PTs and latest ratings.

09/05/2018 Broker: Oppenheimer Rating: Buy New Target: $20.0000 Maintain
16/04/2018 Broker: Roth Capital Rating: Buy New Target: $27.0000 Maintain
11/04/2018 Broker: Leerink Swann Rating: Buy New Target: $20.0000 Maintain
11/04/2018 Broker: Evercore Rating: Buy
28/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $18.0000 Initiate
28/03/2018 Broker: Leerink Swann Rating: Buy New Target: $16.0000 Maintain
21/03/2018 Broker: Oppenheimer Rating: Buy Maintain
16/03/2018 Broker: SunTrust Rating: Buy New Target: $19.0 Maintain
16/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $16.0 Maintain
15/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $16.0 Maintain

CBAY hit $12.21 during the last trading session after $0.45 change.CymaBay Therapeutics, Inc. has 1.07 million shares volume, 0.83% up from normal. CBAY is uptrending and has moved 197.77% since May 16, 2017. CBAY outperformed by 186.22% the S&P 500.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases.The firm is valued at $717.57 million. It engages in developing seladelpar , a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout.Last it reported negative earnings. The companyÂ’s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.

For more CymaBay Therapeutics, Inc. (NASDAQ:CBAY) news brought out recently go to: Globenewswire.com, Nasdaq.com, Seekingalpha.com, Nasdaq.com or Streetinsider.com. The titles are as follows: “CymaBay to Report First Quarter 2018 Financial Results on Tuesday, May 8” brought out on May 01, 2018, “CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic …” on May 08, 2018, “CymaBay Makes Progress With Seladelpar” with a publish date: April 30, 2018, “Report: Developing Opportunities within CymaBay Therapeutics, IAC/InterActiveCorp, Axcelis Technologies, La Quinta …” and the last “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” with publication date: May 15, 2018.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.